The clinical effect analysis of Benazepril combined with Irbesartan and Atorvastatin in the treatment of early diabetic nephropathy
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
目的：观察贝那普利、厄贝沙坦联合阿托伐他汀在治疗早期糖尿病肾病患者中的疗效。方法选取我科住院的糖尿病肾病患者85例，随机分成3组，A组（贝那普利组10mg/d）27例，B组（贝那普利10mg/d +厄贝沙坦组150 mg/d）23例，C组（贝那普利10mg/d +厄贝沙坦150 mg/d +阿托伐他汀组10 mg/d）35例，全部病例连续治疗12周后，观察患者治疗前后血压、血清胆固醇（TC）、甘油三酯（TG）、血清内生肌酐清除率（Ccr）及24h尿微量白蛋白定量以及治疗后三组间上述各项指标。结果3组患者治疗后收缩压、舒张压及平均动脉压(MAP)较治疗前均有明显降低，差异有统计学意义(P<0．01)， B组、C组治疗后收缩压、舒张压和MAP与A组比较有明显降低（P<0．05）。C组治疗后TC、TG较治疗前有显著下降（p＜0.05），3组患者治疗后血清内生肌酐清除率（C c r）及24h尿微量白蛋白定量均较治疗前有明显改善（p＜0.05），其中C组治疗后血清内生肌酐清除率（C c r）及24h尿白微量蛋白定量较其他2组也有显著差异（p＜0.05）。结论贝那普利、厄贝沙坦和阿托伐他汀联合应用可明显降低血压、血脂及显著改善血清内生肌酐清除率和尿蛋白排泄率。
Objective To investigate the clinical efficacy of Benazepril combined with Irbesartan and Atorvastatin in the treatment of early diabetic nephropathy(DN). Methods 85 patients of diabetic nephropathy(DN) in our hospital were randomly divided into three groups: group A (Benazepril 10mg/d n=27), group B (Benazepril 10mg/d+ Irbesartan 150 mg/d n=23), group C (Benazepril 10mg/d+ Irbesartan 150 mg/d+ Atorvastatin 10 mg/d n=35). BP,TC, TG, the level of Ccr and 24h urinary microalbumin were statistical y analyzed before and after 12 weeks treatment. Results Systolic blood pressure(SBP) 、diastolic blood pressure(DBP) and mean arterial blood pressure(MAP)after treatment in the three groups were significantly lower than those before treatment(p<0.05). SBP, DBP and MAP in group B and group C after treatment were lower than those in group A(p<0.05). After 12 weeks treatment, The levels of TC,TG in group C were decreased significantly(p<0.05). The levels of Ccr and 24h urinary microalbumin in the three groups were significantly improved after treatment than those before treatment(p<0.05).Among the three groups, the levels of Ccr and 24h urinary microalbumin in the group C were of statistical difference compared with those in the other two groups. Conclusion Benazepril combined with Irbesartan and Atorvastatin can decreased the blood pressure、blood lipids significantly and can significantly improve the levels of Ccr and 24h urinary microalbumin of patients with DN.
NETL
NSTL
万方数据
